Cor Vasa 2020, 62(5):521-526 | DOI: 10.33678/cor.2020.090

(Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology - summary of the document prepared by ČKS)

Miloš Táborský^a, Aleš Linhart^b, Jan Pyszko^a, Jindřich Špinar^c, Filip Málek^d, Michal Vrablík^e, Marie Lazárová^a, Jiří Vítovec^c, Lenka Špinarová^c, Jan Bělohlávek^b

^* Autoři originálního textu Heart Failure Association ESC: Petar M. Seferović, Gabriele Fragasso, Mark Petrie et al., jménem Asociace srdečního selhání ESC.

^a I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc

^b II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

^c I. interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně

^d Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

^e III. interní klinika, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.

Keywords: Cardiovascular outcomes, Heart failure, Quality of life, Sodium-glucose co-transporter 2 inhibitors, Type 2 diabetes mellitus

Received: October 2, 2020; Accepted: October 10, 2020; Published: November 1, 2020  Show citation